Press Releases April 1, 2026 08:00 AM

Stryker to announce financial results for its first quarter of fiscal year 2026

Stryker schedules Q1 fiscal 2026 financial results release and webcast on April 30, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SYK

Stryker, a global medical technology company, announced it will release its fiscal year 2026 first quarter financial results on April 30, 2026. The company will issue a press release with summary financials and host a webcast to discuss the performance. The announcement provides investors with a scheduled update but does not contain new financial data or forecasts.

Stryker to announce financial results for its first quarter of fiscal year 2026
SYK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Stryker will report Q1 fiscal 2026 earnings on April 30, including a press release and webcast.
  • The company is a global leader in medical technologies spanning MedSurg, Neurotechnology, and Orthopaedics.
  • The webcast and financial details will be accessible on Stryker's website for investors and interested parties.

Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2026.

Stryker will host a webcast at 4:30 p.m. ET on Thursday, April 30, 2026, to discuss its first quarter 2026 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after the live call ends.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or [email protected] 

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]


Risks

  • The announcement does not provide financial guidance or preliminary results, so market uncertainty remains until results are disclosed.
  • Potential risks include market volatility affecting healthcare and medical technology sectors impacting Stryker's actual performance.
  • Economic factors or supply chain issues could influence Stryker’s operational results, which will be reflected in the upcoming report.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026